STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018 (1)

STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018

01/02/2018

STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018

Bad Vilbel, February 1, 2018 – The Supervisory Board of STADA Arzneimittel AG appointed Peter Goldschmidt today as new Chairman of the Executive Board as of September 1, 2018. Peter Goldschmidt will take over from Dr. Claudio Albrecht who has been the CEO at STADA since September 27, 2017. Since 2013, Peter Goldschmidt serves as the President and Head of North America at Sandoz Inc., responsible for the Company’s North American operations.

Mark Keatley, Chief Financial Officer, and Dr. Barthold Piening, Chief Technical Officer, will keep their positions on the STADA Executive Board.

Contact
STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2–18 / 61118 Bad Vilbel / Phone: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: leslie.iltgen@stada.de

Download in PDF format

STADA: Successfully concluded purchase of the Russian branded product portfolio Aqualor® for the self-medication of sinusitis and sore throat

STADA: Significant renewal of Supervisory Board brought forward by two years – Annual General Meeting 2016 postponed to August 26, 2016

STADA: Legal action against STADA’s Serbian subsidiary has been resolved

News

STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018

STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018

Related Posts